Karyopharm Therapeutics reported $-16656000 in Equity Capital and Reserves for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Amgen AMGN:US USD 3.66B 8M
AstraZeneca AZN:LN USD 37.04B 1.9B
Astrazeneca AZN:US USD 37.04B 1.9B
Avrobio Inc AVRO:US USD 75.37M 22.72M
Biocryst Pharmaceuticals BCRX:US USD -294597000 51.94M
Enanta Pharmaceuticals ENTA:US USD 300.84M 20.5M
GlaxoSmithKline GSK:LN GBP 10.6B 1.45B
Karyopharm Therapeutics KPTI:US USD -16656000 123.62M
Macrogenics MGNX:US USD 142.01M 19.06M
Mirati Therapeutics MRTX:US USD 996.52M 132.54M
Nektar Therapeutics NKTR:US USD 366.64M 45.58M
Novartis NOVN:VX USD 59.34B 1.48B
Novartis NVS:US USD 59.34B 1.48B
Regeneron Pharmaceuticals REGN:US USD 22.66B 1.23B
Roche Holding ROG:VX 27.99B 2.8B
Sangamo Biosciences SGMO:US USD 294.96M 14.2M
Takeda 4502:JP JPY 6.18T 536.95B
Tg Therapeutics TGTX:US USD 58.59M 41.89M
Ultragenyx Pharmaceutical RARE:US USD 352.49M 116.34M
Xencor XNCR:US USD 727.5M 4.8M
YTE INCY:US USD 4.37B 143.47M